2021 ECNP Congress
New Frontiers in Digital Health
Workshop Clinical Research Methods
Research & Innovation
Neuroscience-based Nomenclature (NbN)
New Frontiers in Digital Health Meeting Virtual
Supporting European proposals
ECNP Medicines Chest
Definition Early Career Scientist
Workshop Neuropsychopharmacology Virtual
Workshop Clinical Research Methods Virtual
Early Career Advisory Panel
ECNP corona watch
Top article picks
ECNP in depth: interviews
Our aims and objectives
How we are organised
Past ECNP meetings
H. Lundbeck A/S
List of partners
Industry views - H. Lundbeck A/S
Does good work equal good health in working patients with MDD
What do clinical goals mean to patients with schizophrenia?
Are relapse prevention and functioning sufficiently prioritized in the treatment of schizophrenia?
Should we challenge the way we assess functioning?
Can we be bothered about apathy? Approaching negative symptoms in schizophrenia
Towards a focus on the science in treatment classifications
Targeting what matters most for patients with depression: Strategies for promoting full functional recovery
Getting the patients’ perspective on the impact of antipsychotic side effects – Part 1
Getting the patients’ perspective on the impact of antipsychotic side effects – Part 2
Getting the patients’ perspective on the impact of antipsychotic side effects – Part 3
Early psychosis intervention works, but can we move to prevention?
Treatment outcomes in schizophrenia – what matters to patients?
Patient goals and measuring outcome crucial in MDD
Emotional blunting: unresolved MDD symptom or effect of treatment?
This webpage was developed in collaboration with H. Lundbeck A/S.